UK markets closed
  • NIKKEI 225

    29,100.38
    -584.99 (-1.97%)
     
  • HANG SENG

    29,135.73
    +29.58 (+0.10%)
     
  • CRUDE OIL

    62.55
    -0.83 (-1.31%)
     
  • GOLD FUTURES

    1,778.70
    +8.10 (+0.46%)
     
  • DOW

    33,779.60
    -298.03 (-0.87%)
     
  • BTC-GBP

    40,091.03
    +564.45 (+1.43%)
     
  • CMC Crypto 200

    1,270.38
    +35.97 (+2.91%)
     
  • ^IXIC

    13,766.77
    -148.00 (-1.06%)
     
  • ^FTAS

    3,920.05
    -76.60 (-1.92%)
     

Worldwide Neuralgia Treatment Industry to 2027 - Players Include Allergan, GlaxoSmithKline & Biogen Among Others

Research and Markets
·6-min read

Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global neuralgia treatment market size is predicted to reach USD 2.83 billion by 2027, according to the study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

The neuralgia treatment market is expected to witness significant growth owing to the increasing incidences of diabetes and trigeminal neuralgia. Furthermore, multiple sclerosis is also one of factors which can cause neuralgia. Multiple sclerosis decreases the body immunity owing to the neurodegenerative condition which affects the myelin sheath that can cause neuralgia. This is likely to drive market demand over the forecast period.

The potential drug candidates and the expected drug approval is expected to stimulate the global market, with high concentration of pharmaceutical companies engaged in the research & development of novel drugs for neuralgia treatment. For instance, U.S-based drug manufacturer, Biogen Inc. is developing BIIB074 (Vixotrigine) for the treatment of trigeminal neuralgia and is currently in phase II.

Market participants such as Allergan Plc, GlaxoSmithKline Plc., Biogen, Inc., Abbott Laboratories, PixarBio Corporation, Merz Pharma GmbH, Trigemina Inc., Pfizer Inc., Novartis, Lupin, and others. are some of the key players operating in the global market. Biohaven pharmaceuticals has Rimegepant in the phase II clinical trials and it is estimated to be completed by December 2020. The drug is a potent antagonist of the CGRP receptor. The receptor is responsible for neural sensitization and neuropathic pain.

In May 2020, CODA Biotherapeutics, Inc. (CODA), the U.S.-based clinical stage pharmaceutical company currently in the process of developing gene therapy based chemogenetic platform announced the collaboration with the Facial Pain Research Foundation (FPRF) to utilize company's proprietary platform to develop potential therapies and treatment options for the trigeminal neuralgia and other neurological conditions.

The analyst has segmented the neuralgia treatment market report on the basis of treatment, indication, distribution channel, and region.

Key Topics Covered:

1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. Neuralgia Treatment Market Insights
4.1. Neuralgia Treatment - Industry snapshot
4.2. Neuralgia Treatment Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. High incidence rate of Neuralgia
4.2.1.2. Sports injuries causing neuro-degenrative disorders
4.2.2. Restraints and Challenges
4.2.2.1. High cost of treatment
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Neuralgia Treatment Market Industry trends

5. Neuralgia Treatment Market Assessment by Treatment
5.1. Key Findings
5.2. Introduction
5.2.1. Global Neuralgia Treatment Market, By Treatment, 2016-2027 (USD Million)
5.3. Drug Based
5.3.1. Global Neuralgia Treatment Market, by Drug Based, by Region, 2016-2027 (USD Million)
5.3.2. Anticonvulsant Medicines
5.3.2.1. Anticonvulsant Medicines Market, by Region, 2016-2027 (USD Million)
5.3.2.2. Carbamazepine
5.3.2.2.1. Carbamazepine Market, by Region, 2016-2027 (USD Million)
5.3.2.3. Oxcarbazepine
5.3.2.3.1. Oxcarbazepine Market, by Region, 2016-2027 (USD Million)
5.3.2.4. Topiramate
5.3.2.4.1. Topiramate Market, by Region, 2016-2027 (USD Million)
5.3.2.5. Gabapentin
5.3.2.5.1. Gabapentin Market, by Region, 2016-2027 (USD Million)
5.3.2.6. Pregabalin
5.3.2.6.1. Pregabalin Market, by Region, 2016-2027 (USD Million)
5.3.2.7. Clonazepam
5.3.2.7.1. Clonazepam Market, by Region, 2016-2027 (USD Million)
5.3.2.8. Phenytoin
5.3.2.8.1. Phenytoin Market, by Region, 2016-2027 (USD Million)
5.3.2.9. Lamotrigine
5.3.2.9.1. Lamotrigine Market, by Region, 2016-2027 (USD Million)
5.3.2.10. Valproic Acid
5.3.2.10.1. Valproic Acid Market, by Region, 2016-2027 (USD Million)
5.3.3. Tricyclic Antidepressants
5.3.3.1. Tricyclic Antidepressants Market, by Region, 2016-2027 (USD Million)
5.3.3.2. Amitriptyline
5.3.3.2.1. Amitriptyline Market, by Region, 2016-2027 (USD Million)
5.3.3.3. Nortriptyline
5.3.3.3.1. Nortriptyline Market, by Region, 2016-2027 (USD Million)
5.4. Surgery
5.4.1. Global Neuralgia Treatment Market, by Surgery, by Region, 2016-2027 (USD Million)
5.4.2. Balloon Compression
5.4.2.1. Balloon Compression Market, by Region, 2016-2027 (USD Million)
5.4.3. Glycerol Injection
5.4.3.1. Glycerol Injection Market, by Region, 2016-2027 (USD Million)
5.4.4. Radiofrequency Thermal Lesioning
5.4.4.1. Radiofrequency Thermal Lesioning Market, by Region, 2016-2027 (USD Million)
5.4.5. Stereotactic Radiosurgery
5.4.5.1. Stereotactic Radiosurgery Market, by Region, 2016-2027 (USD Million)
5.4.6. Microvascular Decompression
5.4.6.1. Microvascular Decompression Market, by Region, 2016-2027 (USD Million)

6. Global Neuralgia Treatment Market, by End Use
6.1. Key Findings
6.2. Introduction
6.2.1. Global Neuralgia Treatment Market, By End Use, 2016-2027 (USD Million)
6.3. Hospital & Clinics
6.3.1. Global Neuralgia Treatment Market, by Hospital & Clinics, By Region, 2016-2027 (USD Million)
6.4. Ambulatory Surgery Centers
6.4.1. Global Neuralgia Treatment Market, by Ambulatory Surgery Centers, by Region, 2016-2027 (USD Million)
6.5. Others
6.5.1. Global Neuralgia Treatment Market, by Others, by Region, 2016-2027 (USD Million)

7. Neuralgia Treatment Market Assessment by Geography
7.1. Key findings
7.2. Introduction
7.2.1. Neuralgia Treatment Market Assessment, By Geography, 2016-2027 (USD Million)
7.3. Neuralgia Treatment Market - North America
7.5. Neuralgia Treatment Market - Asia-Pacific
7.6. Neuralgia Treatment Market - Middle East & Africa
7.7. Neuralgia Treatment Market - Latin America

8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles
9.1. Allergan Plc
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Developments
9.2. Merz Pharma GmbH & Co.
9.3. Abbott Laboratories
9.4. Trigemina Inc.
9.5. Pfizer Inc.
9.6. Novartis
9.7. GlaxoSmithKline Plc.
9.8. Lupin
9.9. Cadila Healthcare Limited
9.10. Lundbeck Pharmaceuticals LLC
9.11. Biogen

For more information about this report visit https://www.researchandmarkets.com/r/2gwnhp

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900